- Home
- MGIC vs ERAS Comparison
MGIC vs ERAS Comparison
Compare MGIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGIC | ERAS |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MGIC | ERAS |
|---|---|---|
| Price | $17.38 | $13.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $18.00 | $5.78 |
| AVG Volume (30 Days) | 41.1K | ★ 3.8M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | N/A | ★ 16.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.65 | $1.01 |
| 52 Week High | $28.00 | $14.17 |
Technical Indicators
Market Signals| Indicator | MGIC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 30.58 | 75.80 |
| Support Level | $15.14 | $1.27 |
| Resistance Level | $21.16 | N/A |
| Average True Range (ATR) | 0.94 | 0.73 |
| MACD | -0.43 | -0.07 |
| Stochastic Oscillator | 3.18 | 76.31 |
Price Performance
Historical ComparisonAbout MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.